These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 7770726)

  • 21. Relationship between internalization and cytotoxicity of ricin A-chain immunotoxins.
    Preijers FW; Tax WJ; De Witte T; Janssen A; vd Heijden H; Vidal H; Wessels JM; Capel PJ
    Br J Haematol; 1988 Nov; 70(3):289-94. PubMed ID: 3264717
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Degradation of radioiodinated B cell monoclonal antibodies: inhibition via a FCgamma-receptor-II-mediated mechanism and by drugs.
    Vervoordeldonk SF; Balkenende AY; van den Berg H; von dem Borne AE; van der Schoot CE; Van Leeuwen EF; Slaper-Cortenbach IC
    Cancer Immunol Immunother; 1996 Jan; 42(1):24-30. PubMed ID: 8625363
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Internalization of the cytotoxic molecules of T101 F(ab')2-(ricin-A-chain) immunotoxin into human T-leukemic cells.
    Ravel S; Casellas P
    Eur J Biochem; 1990 Sep; 192(2):469-73. PubMed ID: 2209602
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CD22, a B lymphocyte-specific adhesion molecule that regulates antigen receptor signaling.
    Tedder TF; Tuscano J; Sato S; Kehrl JH
    Annu Rev Immunol; 1997; 15():481-504. PubMed ID: 9143697
    [TBL] [Abstract][Full Text] [Related]  

  • 25. B-cell restricted saporin immunotoxins: activity against B-cell lines and chronic lymphocytic leukemia cells.
    Bregni M; Siena S; Formosa A; Lappi DA; Martineau D; Malavasi F; Dorken B; Bonadonna G; Gianni AM
    Blood; 1989 Feb; 73(3):753-62. PubMed ID: 2465042
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Delivery of saporin to human B-cell lymphoma using bispecific antibody: targeting via CD22 but not CD19, CD37, or immunoglobulin results in efficient killing.
    Bonardi MA; French RR; Amlot P; Gromo G; Modena D; Glennie MJ
    Cancer Res; 1993 Jul; 53(13):3015-21. PubMed ID: 7686448
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CD22, a B cell-specific immunoglobulin superfamily member, is a sialic acid-binding lectin.
    Sgroi D; Varki A; Braesch-Andersen S; Stamenkovic I
    J Biol Chem; 1993 Apr; 268(10):7011-8. PubMed ID: 8463234
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The epitope specificity and tissue reactivity of four murine monoclonal anti-CD22 antibodies.
    Li JL; Shen GL; Ghetie MA; May RD; Till M; Ghetie V; Uhr JW; Janossy G; Thorpe PE; Amlot P
    Cell Immunol; 1989 Jan; 118(1):85-99. PubMed ID: 2463099
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of the ligand-binding domains of CD22, a member of the immunoglobulin superfamily that uniquely binds a sialic acid-dependent ligand.
    Engel P; Wagner N; Miller AS; Tedder TF
    J Exp Med; 1995 Apr; 181(4):1581-6. PubMed ID: 7535343
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of alpha2,6-linked sialic acid on anti-IgM antibody-induced apoptosis in Ramos cells.
    Azuma Y; Sakanashi M; Matsumoto K
    Glycoconj J; 2001 May; 18(5):419-24. PubMed ID: 11925509
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(+), CD22(+) B cell lymphoma.
    Messmann RA; Vitetta ES; Headlee D; Senderowicz AM; Figg WD; Schindler J; Michiel DF; Creekmore S; Steinberg SM; Kohler D; Jaffe ES; Stetler-Stevenson M; Chen H; Ghetie V; Sausville EA
    Clin Cancer Res; 2000 Apr; 6(4):1302-13. PubMed ID: 10778955
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The generation of immunotoxins using chimeric anti-CD22 antibodies containing mutations which alter their serum half-life.
    Pop LM; Liu X; Ghetie V; Vitetta ES
    Int Immunopharmacol; 2005 Jul; 5(7-8):1279-90. PubMed ID: 15914332
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cytotoxic potential of anti-CD7 immunotoxin (WT1-ricin A) to purge ex vivo malignant T cells in bone marrow.
    Preijers FW; De Witte T; Wessels JM; Meyerink JP; Haanen C; Capel PJ
    Br J Haematol; 1989 Feb; 71(2):195-201. PubMed ID: 2784323
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Complete sustained response of a refractory, post-transplantation, large B-cell lymphoma to an anti-CD22 immunotoxin.
    Senderowicz AM; Vitetta E; Headlee D; Ghetie V; Uhr JW; Figg WD; Lush RM; Stetler-Stevenson M; Kershaw G; Kingma DW; Jaffe ES; Sausville EA
    Ann Intern Med; 1997 Jun; 126(11):882-5. PubMed ID: 9163289
    [No Abstract]   [Full Text] [Related]  

  • 35. CD22 associates with the human surface IgM-B-cell antigen receptor complex.
    Leprince C; Draves KE; Geahlen RL; Ledbetter JA; Clark EA
    Proc Natl Acad Sci U S A; 1993 Apr; 90(8):3236-40. PubMed ID: 8475064
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-CD6-blocked ricin: an anti-pan T-cell immunotoxin.
    Collinson AR; Lambert JM; Liu Y; O'Dea C; Shah SA; Rasmussen RA; Goldmacher VS
    Int J Immunopharmacol; 1994 Jan; 16(1):37-49. PubMed ID: 8150554
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The ligand-binding domain of CD22 is needed for inhibition of the B cell receptor signal, as demonstrated by a novel human CD22-specific inhibitor compound.
    Kelm S; Gerlach J; Brossmer R; Danzer CP; Nitschke L
    J Exp Med; 2002 May; 195(9):1207-13. PubMed ID: 11994426
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Masking and unmasking of the sialic acid-binding lectin activity of CD22 (Siglec-2) on B lymphocytes.
    Razi N; Varki A
    Proc Natl Acad Sci U S A; 1998 Jun; 95(13):7469-74. PubMed ID: 9636173
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of the cytotoxic activity of the immunotoxins with different internalization rate.
    Tonevitsky AG; Agapov II; Mechetner EB; Ershova GV; Toptygin AYu ; Sarma T; Shamshiev AT; Pfueller U
    Biochem Mol Biol Int; 1993 Dec; 31(6):1059-69. PubMed ID: 8193589
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy.
    Amlot PL; Stone MJ; Cunningham D; Fay J; Newman J; Collins R; May R; McCarthy M; Richardson J; Ghetie V
    Blood; 1993 Nov; 82(9):2624-33. PubMed ID: 8219217
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.